|By Marketwired .||
|March 5, 2014 05:01 PM EST||
NEWARK, NJ -- (Marketwired) -- 03/05/14 -- A six-minute breath test accurately identified women with early stage breast cancer or an abnormal screening mammogram.
The study of 244 women, published in the scientific journal PLOS ONE, was performed at three breast cancer centers: Newark Beth Israel hospital in Newark, NJ, Swedish Medical Center in Seattle, WA and Maastricht University in the Netherlands.
Menssana Research CEO Dr. Michael Phillips said: "Researchers discovered 20 years ago that women with breast cancer have abnormal volatile chemicals in their breath. But only recently have we learned how to use these chemicals for early screening."
"A negative result on the breath test was especially useful, because it ruled out both breast cancer and an abnormal screening mammogram with almost 100% accuracy. Most normal healthy woman will have a negative breath test result, and they would probably not need a routine screening mammogram.
"Mammograms are often uncomfortable, painful, and require a dose of potentially hazardous radiation. In contrast, a screening breath test is safe, painless, non-invasive and does not expose patients to any radiation."
Dr. Phillips emphasized that screening breath tests for breast cancer should be considered experimental until these findings are confirmed in larger studies. Nor does a positive breath test confirm a breast cancer diagnosis. Overall test accuracy for breast cancer was around 80%, so women with a positive breath test should have other tests including a mammogram.
Breast cancer is the most commonly diagnosed cancer in women and it is second only to lung cancer in overall cancer deaths. The National Cancer Institute estimated that more than 232,000 women would be diagnosed with breast cancer in 2013 and nearly 40,000 would die of the disease. To reduce the number of breast cancer deaths, many countries have established screening mammography programs to detect early-stage disease when it is easiest to cure.
The US National Institutes of Health and the Dutch Pink Ribbon Foundation funded the research.
About us: Menssana Research develops breath tests for diseases including breast cancer, lung cancer, tuberculosis, and heart transplant rejection. The 6-minute Breathlink test has European Regulatory Approval (CE Mark) for both breast cancer and pulmonary tuberculosis. FDA has approved the Heartsbreath test for heart transplant rejection with a Humanitarian Device Exemption.
Jul. 29, 2016 11:46 AM EDT
Jul. 29, 2016 11:30 AM EDT Reads: 1,214
Jul. 29, 2016 11:15 AM EDT Reads: 665
Jul. 29, 2016 11:15 AM EDT Reads: 1,331
Jul. 29, 2016 11:00 AM EDT Reads: 778
Jul. 29, 2016 11:00 AM EDT Reads: 418
Jul. 29, 2016 11:00 AM EDT Reads: 490
Jul. 29, 2016 11:00 AM EDT Reads: 505
Jul. 29, 2016 10:53 AM EDT Reads: 228
Jul. 29, 2016 10:45 AM EDT Reads: 486
Jul. 29, 2016 09:45 AM EDT Reads: 2,126
For basic one-to-one voice or video calling solutions, WebRTC has proven to be a very powerful technology. Although WebRTC’s core functionality is to provide secure, real-time p2p media streaming, leveraging native platform features and server-side components brings up new communication capabilities for web and native mobile applications, allowing for advanced multi-user use cases such as video broadcasting, conferencing, and media recording.
Jul. 29, 2016 09:45 AM EDT Reads: 1,027
SYS-CON Events announced today that Venafi, the Immune System for the Internet™ and the leading provider of Next Generation Trust Protection, will exhibit at @DevOpsSummit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Venafi is the Immune System for the Internet™ that protects the foundation of all cybersecurity – cryptographic keys and digital certificates – so they can’t be misused by bad guys in attacks...
Jul. 29, 2016 09:45 AM EDT Reads: 1,462
In his session at Cloud Expo, Robert Cohen, an economist and senior fellow at the Economic Strategy Institute, will provide economic scenarios that describe how the rapid adoption of software-defined everything including cloud services, SDDC and open networking will change GDP, industry growth, productivity and jobs. This session will also include a drill down for several industries such as finance, social media, cloud service providers and pharmaceuticals.
Jul. 29, 2016 09:07 AM EDT Reads: 290
Security, data privacy, reliability, and regulatory compliance are critical factors when evaluating whether to move business applications from in-house, client-hosted environments to a cloud platform. Quality assurance plays a vital role in ensuring that the appropriate level of risk assessment, verification, and validation takes place to ensure business continuity during the migration to a new cloud platform.
Jul. 29, 2016 08:00 AM EDT Reads: 455